Thermo Fisher Positioned As Biopharma's Partner Of Choice
1. TMO's stock has lagged 27% since 2021; analysts expect recovery. 2. Recent earnings beat estimates; revenue growth is positive. 3. William Blair sees potential upside to $598 per share by 2026. 4. M&A activity will drive growth; TMO is a biopharma partner of choice. 5. Investment of $2 billion in the U.S. announced for tariff navigation.